期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 89, 期 4, 页码 1282-1290出版社
WILEY
DOI: 10.1111/bcp.15676
关键词
COVID-19; monoclonal antibody; regdanvimab; SARS-COV-2
This study evaluated the efficacy and safety of regdanvimab, an anti-SARS-COV-2 monoclonal antibody, for the treatment of confirmed COVID-19. Eight studies involving 4793 patients were included, showing significant differences in terms of hospital stay, clinical recovery, disease progression, oxygen therapy need, and duration. However, no significant differences were found in mortality rate, mechanical ventilation need, and hospital admission rate. The incidence of adverse events was similar in both groups. Further research is needed to confirm these findings.
AimsThis study aimed to evaluate the efficacy and safety of regdanvimab, an anti-SARS-COV-2 monoclonal antibody approved by the European Medicines Agency in November 2021, for the treatment of confirmed COVID-19 disease. MethodsCochrane Library, PubMed, medRxiv and Google Scholar were searched for relevant evidence up to October 27, 2022. The quality of included studies was assessed using the Cochrane risk of bias tools. Data were analysed using RevMan software. ResultsEight studies involving 4793 patients were included. A significant difference was observed between the regdanvimab and no-regdanvimab groups in terms of length of hospital stay (mean difference [MD] = -1.15, 95% confidence interval [CI]: -1.80 to -0.43), clinical recovery (odds ratio [OR] = 2.09, 95% CI: 1.38 to 3.18), disease progression (OR = 0.23, 95% CI: 0.16 to 0.33), the need for oxygen therapy (OR = 0.33, 95% CI: 0.25 to 0.43) and duration of oxygen therapy (MD = -3.00, 95% CI: -4.44 to -1.56). However, no significant difference was detected between 2 groups regarding mortality rate (OR = 0.46, 95% CI: 0.11 to 1.89), need for mechanical ventilation (OR = 0.39, 95% CI: 0.08 to 1.89) and hospital admission rate (OR = 0.61, 95% CI: 0.35 to 1.03). The incidence of adverse events was similar in both groups (OR = 0.96, 95% CI: 0.77 to 1.18). ConclusionRegdanvimab was not effective in reducing mortality and hospital admission rate in patients with mild to moderate COVID-19, but it was effective in improving other efficacy outcomes. Further research is needed to confirm these findings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据